KALA PHARMACEUTICALS, INC. : Regulation FD Disclosure (form 8-K)

Item 7.01. Regulation FD Disclosure.

On September 17, 2020, Kala Pharmaceuticals, Inc. (the "Company") made available a presentation entitled "Virtual Investor & Analyst Event: Understanding the Potential of EYSUVISTM for the Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease" through the "Investors & Media" section of the Company's website (http://www.kalarx.com) under "Events and Presentations". Any other information contained in, or that can be accessed through, the Company's website is not a part of this filing.

The information in this Current Report on Form 8-K is furnished to comply with Item 7.01 of Form 8-K, and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

© Edgar Online, source Glimpses